TITLE:
Advances in Lung Cancer and Treatment Research
AUTHORS:
Xiaofei Wang, Baohui Han
KEYWORDS:
NSCLC; EGFR-Targeting Tyrosine Kinase
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.8A,
August
21,
2013
ABSTRACT: With the
advances in surgery, chemotherapy, and radiotherapy over the last decades, the
treatment strategies of lung cancer has been largely changed. In this review,
we summarize recent advances in lung cancer and treatment research. We discuss
current clinical management, highlight stage-specific
therapy approaches, chemotherapy options for advanced-stage of non-small-cell
lung cancer (NSCLC) patients, along with new agents such as epidermal growth
factor receptor (EGFR)-targeting tyrosine kinase inhibitors erlotinib and
gefitinib, and the anaplastic lymphoma kinase (ALK) inhibitor crizotinib. We also
give an outlook into NSCLC disease biology, focuse on the importance of EGFR activating mutations and the role of the tumor-microenvironment.
Finally we summarize the new recommendations in treating small-cell-lung cancer
(SCLC).